Recent Securities Litigations
Inovio Pharmaceuticals Inc. Common Stock (NASDAQ: INO)
According to the Complaint, Inovio Pharmaceuticals, Inc. purports to be a “biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from . . . infectious diseases.”
The Complaint alleges that during the Class Period, Inovio made misleading statements about the company’s development of a purported vaccine for the novel coronavirus, artificially inflating the company’s share price and resulting in significant investor losses. Specifically, the Complaint alleges that Defendants capitalized on widespread COVID-19 fears by falsely claiming that Invovio had developed a vaccine for COVID-19.